“…Within the last decade, increasingly, attempts were made to improve EDA approaches, e.g., by including fractionation methods for more polar compounds (Lubcke-von Varel et al 2008;Meinert et al 2007), methods for addressing the bioavailability within the fractionation approach Schwab and Brack 2007), incorporating structure generation and mass spectral classifiers for identifying of unknown substances (Schymanski et al 2008), and the use of additional biological endpoints, such as gene expression alterations (Scholz et al 2008), teratogenicity, and genotoxicity (Kosmehl et al 2007), and steroidogenesis (Hecker et al 2007). One particular topic that has concerned risk assessors and regulator during the past two decades is the issue of endocrine disruption.…”